Systemic sclerosis or scleroderma is an autoimmune condition that cause thickening and hardening of the skin, but can also affect internal organs. There are two major subsets of scleroderma: the limited cutaneous systemic sclerosis (lcSSc) that usually affects the skin of the face, neck, lower legs or lower arms, but can also lead to internal organ complications, and the diffuse cutaneous systemic sclerosis (dcSSc) that may affect blood circulation and internal organs, as well as the skin. To date there is no drug that has been definitively proven to cure or modify the course of scleroderma. However, there is emerging evidence that immunosuppression and specifically mycophenolate mofetil (MMF) may be beneficial in lcSSc. The MINIMISE-Pilot trial would be an important first step to evaluate the risk and potential benefit to this disease group. MMF as the intervention of choice is both appropriate and timely, as it has been routinely used in the management of dcSSc. The aim of this pilot trial is to explore whether the immunosuppressive agent MMF can slow down disease progression in patients with lcSSc compared to the current standard of care alone. This pilot trial will also provide critical information for the development of a future large trial that could potentially transform lcSSc patient management.
The MINIMISE-Pilot trial aims to explore whether the immunosuppressive agent mycophenolate mofetil (MMF) at a target dose of 2g daily can slow down disease progression in patients with limited cutaneous systemic sclerosis (lcSSc) compared to the current standard of care alone. This pilot trial will also provide critical information for the development of a future large trial that could potentially transform lcSSc patient management. This is an open label randomised prospective trial that will recruit 120 participants aged 18 and older with limited cutaneous systemic sclerosis across 13 sites in the UK. Following a screening visit, eligible participants will attend a baseline visit where they will be randomly allocated into one of two groups; MMF or Control. Those in the first group are given mycophenolate mofetil (MMF) taken daily by mouth for up to 96 weeks, in addition to their background Standard of Care medication for SSc related symptoms. Those in the second group will not receive any MMF but will remain on their standard of care medication alone. Participants are expected to be followed up for a minimum of 48 weeks or a maximum of 96 weeks. The trial will involve five (5) clinic visits which are expected to be carried out at the same time of the participants' normal hospital appointment with their scleroderma specialist. Participants from both groups will have the same assessments. Participants are expected to return to the clinics at Week 24, 48, 72 and 96. However, participants allocated to the MMF group will have additional blood samples taken for safety monitoring every 2 weeks for the first 8 weeks, then every 4 weeks for the following 12 weeks. Thereafter, every 12 weeks up to their final visit. All the participants will receive four (4) routine telephone calls in between their clinic visits.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
120
Mycophenolate Mofetil oral tablet twice daily for up to 96 weeks
Royal United Hospitals Bath Nhs Foundation Trust
Bath, United Kingdom
Southmead Hospital - NORTH BRISTOL NHS TRUST
Bristol, United Kingdom
Darlington Memorial Hospital - County Durham and Darlington NHS Foundation Trust
Darlington, United Kingdom
Ninewells Hospital - NHS Tayside
Dundee, United Kingdom
Chapel Allerton Hospital - LEEDS TEACHING HOSPITALS NHS TRUST
Leeds, United Kingdom
Aintree University Hospital NHS Foundation Trust
Liverpool, United Kingdom
Royal Free Hospital - Royal Free NHS Foundation Trust
London, United Kingdom
Manchester Royal Infirmary - Manchester University NHS Foundation Trust
Manchester, United Kingdom
Salford Hospital - Northern Care Alliance NHS Foundation Trust
Manchester, United Kingdom
Freeman Hospital - THE NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST
Newcastle, United Kingdom
...and 2 more locations
The total number of lcSSc patients screened during the 12 month recruitment period, measured from information provided on the site Screening Logs
The total number of lcSSc patients screened will be captured on detailed screening logs
Time frame: From first site activation up to a period of 12 months
The proportion of participants who provide consent during the 12 month recruitment period, measured from information provided on the site Screening Logs
Participant informed consent will be captured in detailed screening logs
Time frame: From first site activation up to a period of 12 months
The proportion of participants who meet the eligibility criteria during the 12 month recruitment period, measured from information provided on the site Screening Logs
Information on participants who meet the eligibility criteria will be captured on detailed screening logs
Time frame: From first site activation up to a period of 12 months
Adherence to trial treatment by participants randomised to the MMF arm as assessed by the Participant Dosing Diaries.
Participant self-reported adherence using participant dosing diaries to be completed daily. Diaries will be provided to all participants randomised to MMF to record their daily trial medication intake, in addition to any dose modifications and dose interruptions for the duration of their time in the study.
Time frame: From Baseline, up until a minimum of 48 weeks or a maximum of 96 weeks
Drug adherence rate from participants randomised to the MMF arm, measured by Pharmacy Accountability Logs
Pharmacy dispensing accountability logs will record the number of pills dispensed at each visit and the number of pills returned by the participant.(i.e. pill count) The number of pills taken is calculated by subtracting the count of the number of pills remaining from the total number of pills dispensed. The drug adherence rate is then calculated by dividing the number of pills taken by number of days elapsed since the last dispense.
Time frame: From first participant dispensing, through study completion up to 36 months
Adherence to the study protocol by participating sites as assessed by the number of protocol deviations reported using the Protocol Deviation Reports
Sites to report deviations and sponsor protocol compliance reviews during central, remote and on-site monitoring to be reported in Protocol Deviation Reports.
Time frame: From Screening, through study completion up to 36 months
The proportion of participants intolerant to MMF who discontinue trial treatment from Baseline for a minimum of 48 weeks or a maximum of 96 weeks as assessed by the Participant withdrawal Logs
The number of participants who withdraw from trial treatment ONLY will be recorded using detailed Participant Withdrawal Logs
Time frame: From Baseline, up until a minimum of 48 weeks or a maximum of 96 weeks
The total number of participants randomised to MMF who reach the target dose of 2g a day, measured by medication intake information captured in the Participant Dosing Diaries
Self-reported: Participant Dosing Diaries will be provided to all participants randomised to MMF to record dose escalation information and daily intake of the IMP .
Time frame: From Baseline through to study completion for a minimum of 48 weeks or a maximum of 96 weeks
The total number of participants randomised to MMF and Control who reach a clinical worsening of disease progression, measured by the modified Rodnan Skin Score (mRSS) from Baseline, every 6 months until Final trial visit.
Validated physical examination method for estimating skin induration. It is scored on a 0 (normal) to 3+ (severe induration) ordinal scales over 17 body areas, with a maximum score of 51 and is used to categorise severity of SSc. Minimally clinically significant difference in mRSS is 3-5 points. The measurement of time to clinically important disease progression will demonstrate a clinically important advantage of active treatment compared with no immunosuppression if a beneficial effect is found.
Time frame: From Baseline, every 6 months, through study completion up until a minimum of 48 weeks or a maximum of 96 weeks
The number of participant loss to follow- up as assessed by the Participant Withdrawal Logs
The number of participant loss to follow -up in each group (MMF or control) will be recorded using detailed Participant Withdrawal Logs
Time frame: From Baseline, through study completion up until a minimum of 48 weeks or a maximum of 96 weeks
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 from Baseline for a minimum of 48 weeks or a maximum of 96 weeks
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 from Baseline for a minimum of 48 weeks or a maximum of 96 weeks
Time frame: From Baseline, through study completion for a minimum of 48 weeks or a maximum of 96 weeks
Number of reported deaths Baseline
Participants self report, review of hospital records
Time frame: From Baseline , through study completion, up to 36 months
Changes in functional ability from Baseline for a minimum of 48 weeks or a maximum of 96 weeks as measured by the Scleroderma Assessment Questionnaire
The Scleroderma Assessment Questionnaire is a self-assessed measure ranging from 0-3 (where 0 = without difficulty and 3 = unable to do) for several questions including vascular, respiratory, gastrointestinal, musculoskeletal, and overall disease status with 23 questions divided into 4 groups.
Time frame: From Baseline, every 6 months, through study completion up until a minimum of 48 weeks or a maximum of 96 weeks
Quality of Life as measured by the EQ5-5D-5L Questionnaire from Baseline for a minimum of 48 weeks or a maximum of 96 weeks
EQ-5D- 5L is a participant self -reported questionnaire which evaluates the generic quality of life at the time of completion. It comprises of one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Respondents are asked to choose the statement in each dimension that best describes their health status. Their responses are coded as a number (1, 2, or 3) that corresponds to the respective level of severity: 1 indicates no problems, 2 some problems, and 3 extreme problems
Time frame: From Baseline, every 6 months, through study completion up until a minimum of 48 weeks or a maximum of 96 weeks
Changes in pain and disability from Baseline for a minimum of 48 weeks or a maximum of 96 weeks as measured by the Patient Global Questionnaire.
Self-reported questionnaire assessed by a single question to reflect the participants perspective on their health overall. Rating scale used with a 0-100 response, where 0= has no effect at all, 100= worst possible effect.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: From Baseline, every 6 months, through study completion up until a minimum of 48 weeks or a maximum of 96 weeks
Changes in pain and disability from Baseline for a minimum of 48 weeks or a maximum of 96 weeks as measured by the Physician's Global Questionnaire.
Physician-reported questionnaire assessed by a single question to reflect the participants perspective on their health overall. Rating scale used with a 0-100 response, where 0= has no effect at all, 100= worst possible effect.
Time frame: From Baseline, every 6 months, through study completion up until a minimum of 48 weeks or a maximum of 96 weeks]
Scleroderma skin activity and skin-related health related quality of life from Baseline for a minimum of 48 weeks or a maximum of 96 weeks as measured by PASTUL-SSPRO score
Self-reported questionnaire specifies a grading of skin (normal (0), mild (1), moderate (2), severely (3) thickened) at eight sites corresponding to mRSS with maximum score assigned to each site (PASTUL), and that assesses health-related quality of life (HRQOL) related to skin involvement in SSc. It has 18 items representing 4 HRQOL scales: physical effects, emotional effects, physical function, and social effects. All items are scored from 0 (better) to 6 (worse) (SSPRO).
Time frame: From Baseline, every 6 months, through study completion up until a minimum of 48 weeks or a maximum of 96 weeks